» Articles » PMID: 9435992

Pharmacokinetics and Pharmacodynamics of Sedatives and Analgesics in the Treatment of Agitated Critically Ill Patients

Overview
Specialty Pharmacology
Date 1998 Jan 22
PMID 9435992
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics and pharmacodynamics of sedatives and analgesics are significantly altered in the critically ill. These changes may account for the large differences in drug dosage requirements compared with other patient populations. Drugs that in other settings may be considered short-acting often have significantly altered onset and duration of action in critically ill patients, necessitating a change in dosage. Of the benzodiazepines, lorazepam is the drug whose parameters are the least likely to be altered in critical illness. The presence of active metabolites with other benzodiazepines complicates their use during periods of prolonged use. Similarly, the presence of active metabolites of morphine and pethidine (meperidine) warrants caution in patients with renal insufficiency. The fewer cardiovascular effects seen with high-potency opioids, such as fentanyl and sufentanil, increase their usefulness in haemodynamically compromised patients. The pharmacodynamics of propofol are not significantly altered in the critically ill. Ketamine should be used with a benzodiazepine to prevent the emergence of psychomimetic reactions. Lower sedative doses of benzodiazepines and anaesthetics may not provide reliable amnesia. Barbiturates and propofol probably do not induce hyperalgesia and lack intrinsic analgesic activity. The antipsychotic agent haloperidol has a calming effect on patients and administration to the point of sedation is generally not necessary. Combinations of sedatives and analgesics are synergistic in producing sedation. The costs of sedation and analgesia are very variable and closely linked to the pharmacokinetics and pharmacodynamics of the drug. Monitoring of sedation and analgesia is difficult in uncooperative patients in the intensive care unit. In the future, specific monitoring tools may assist clinicians in the regulation of infusions of sedative and analgesic agents.

Citing Articles

Evaluating Sedation Strategies for Magnetic Resonance Imaging: A Comprehensive Review of Intravenous Fentanyl, Butorphanol, and Midazolam in Adult and Pediatric Populations.

Verma N, Dahake J Cureus. 2024; 16(4):e58593.

PMID: 38770500 PMC: 11102870. DOI: 10.7759/cureus.58593.


Distribution and elimination kinetics of midazolam and metabolites after post-resuscitation care: a prospective observational study.

Jeong W, Sunwoo J, You Y, Park J, Min J, In Y Sci Rep. 2024; 14(1):4574.

PMID: 38403792 PMC: 10894853. DOI: 10.1038/s41598-024-54968-z.


Haloperidol-Midazolam vs. Haloperidol-Ketamine in Controlling the Agitation of Delirious Patients; a Randomized Clinical Trial.

Aghili M, AkhavanHejazi H, Naderpour Z, Vahidi E, Saeedi M Arch Acad Emerg Med. 2023; 11(1):e61.

PMID: 37840867 PMC: 10568945. DOI: 10.22037/aaem.v11i1.2095.


Protocol for the Ketamine for Postoperative Avoidance of Depressive Symptoms (K-PASS) feasibility study: A randomized clinical trial.

Fritz B, Pennington B, Palanca B, Schweiger J, Willie J, Farber N F1000Res. 2023; 11:510.

PMID: 37483552 PMC: 10362376. DOI: 10.12688/f1000research.121529.1.


A Comparative Analysis Between Ketamine Versus Combination of Midazolam and Haloperidol for Rapid Safe Control of Agitated Patients in Emergency Department: A Systematic Review.

Zaki H, Shaban E, Bashir K, Iftikhar H, Zahran A, Salem E Cureus. 2022; 14(6):e26162.

PMID: 35891834 PMC: 9302860. DOI: 10.7759/cureus.26162.


References
1.
Macfie A, Magides A, Reilly C . Disposition of alfentanil in burns patients. Br J Anaesth. 1992; 69(5):447-50. DOI: 10.1093/bja/69.5.447. View

2.
Brazinsky S, Basile C, Lanken P . Use of sedating drugs and neuromuscular blocking agents in patients requiring mechanical ventilation for respiratory failure. A national survey. JAMA. 1991; 266(20):2870-5. View

3.
Pentikainen P, Valisalmi L, Himberg J, Crevoisier C . Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989; 29(3):272-7. DOI: 10.1002/j.1552-4604.1989.tb03327.x. View

4.
Klotz U, Kanto J . Pharmacokinetics and clinical use of flumazenil (Ro 15-1788). Clin Pharmacokinet. 1988; 14(1):1-12. DOI: 10.2165/00003088-198814010-00001. View

5.
Ehrnebo M . Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration. J Pharm Sci. 1974; 63(7):1114-8. DOI: 10.1002/jps.2600630717. View